<DOC>
	<DOC>NCT01084005</DOC>
	<brief_summary>The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatment in elderly patients with T2DM with insufficient glycaemic control</brief_summary>
	<brief_title>Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criteria: 1. Type 2 diabetes mellitus 2. HbA1c &gt;= 7.0% 3. Age &gt;= 70 years 4. Signed and dated written informed consent Exclusion criteria: 1. Myocardial infarction, stroke or TIA within 3 months prior to informed consent 2. Impaired hepatic function 3. Treatment with glitazones, GLP1 analogues, DPP4 inhibitors or rapid acting or premixed insulins 4. Treatment with antiobesity drugs</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>